Document Classification

Section Type: RESULTS

Text: The benefits were consistent among those undergoing percutaneous coronary intervention (PCI) [9. 6 % for clopidogrel, 13. 2 % for placebo ; relative risk (RR), 0. 72 ; 95 % CI, 0. 57 to 0. 90], coronary artery bypass grafting (CABG) surgery (14. 5 % for clopidogrel 16. 2 % for placebo ; RR, 0. 89 ; 95 % CI, 0. 71 to 1. 11), and medical therapy only (8. 1 % for clopidogrel, 10. 0 % for placebo ; RR, 0. 80 ; 95 % CI, 0. 69 to 0. 92 ; test for interaction among strata, 0. 53).